Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Ustekinumab clinical trials

Also listed in trial records as Stelara, CNTO 1275, USTE
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 23 trials in our Canada, USA, Belgium, China, Germany, Poland, UK, France, Spain, Italy, Czechia, Japan, South Korea, Australia, Netherlands, Austria, Denmark, Brazil, Switzerland, Turkey, Israel, Sweden, Mexico, Taiwan, Portugal, Norway, India and Egypt registers that name Ustekinumab as an intervention. Synced 13 Nov 2026
23Current trials
13Recruiting now
20Lead sponsors
28Country registers
At a glance

Ustekinumab is named as an intervention in 23 current clinical trials in our Canada, USA, Belgium, China, Germany, Poland, UK, France, Spain, Italy, Czechia, Japan, South Korea, Australia, Netherlands, Austria, Denmark, Brazil, Switzerland, Turkey, Israel, Sweden, Mexico, Taiwan, Portugal, Norway, India and Egypt registers. 13 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Janssen Research & Development, LLC (3). The most-studied condition is Crohn Disease. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.

Ustekinumab also has an approved-drug profile on this site (FDA label data): Stelara (Ustekinumab) →

Where Ustekinumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Ustekinumab was Canada, on 12 Dec 2008. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
25 Sep 2009
Stelara
BLA125261 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
16 Jan 2009
Stelara
EMA product page
First centralised authorisation
CACanada (Health Canada)
12 Dec 2008
Stelara
Notice of Compliance 9937
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Ustekinumab

All medicines →
ENNHS England
£4k
2 items dispensed, Sep 2025 to Aug 2026
+100% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$1.36bn
61,157 prescriptions in 2025 · Stelara, Yesintek, Selarsdi
-15% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Ustekinumab works

All drug targets →
  • Interleukin-12 inhibitor Inhibitor
    Target: Interleukin-12
    ChEMBL only
  • Interleukin-23 inhibitor Inhibitor
    Target: Interleukin-23
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • Takayasu arteritisPhase 3
  • Ankylosing spondylitisPhase 3
  • DermatomyositisPhase 3
  • Intestinal obstructionPhase 3
  • Palmoplantar pustulosisPhase 3
  • PolymyositisPhase 3
  • PouchitisPhase 3
  • Psoriasis-related juvenile idiopathic arthritisPhase 3
  • Rheumatoid arthritisPhase 3
  • Systemic lupus erythematosusPhase 3
38 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201835, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6885, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Ustekinumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 5 technology appraisals of Ustekinumab. 5 are current, and 5 of these recommend it for at least some patients.

AppraisalNICE recommendationPublishedStatus
Ustekinumab for treating moderately to severely active ulcerative colitis
NICE TA633
Optimised17 Jun 2020Current
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455
Optimised12 Jul 2017Current
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
NICE TA456
Recommended12 Jul 2017Current
Ustekinumab for treating active psoriatic arthritis
NICE TA340
Optimised4 Jun 2015
Updated 3 Mar 2017
Current
Ustekinumab for treating moderate to severe plaque psoriasis
NICE TA180
Recommended23 Sep 2009
Updated 3 Mar 2017
Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Ustekinumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Ustekinumab

ATC code
L04AC05
ChEMBL
CHEMBL1201835
DrugBank
DB05679
CAS number
815610-63-0
FDA UNII
FU77B4U5Z0
Wikidata
Q420305
Wikipedia
Ustekinumab

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting1357%
  • Active, closed1043%

Trials by phase

  • Observational1043%
  • Phase 3522%
  • Phase 4417%
  • Phase 2/329%
  • Phase 114%
  • Phase 214%
01

Clinical trials of Ustekinumab

23 trials
StudyPhaseStatusLead sponsorRegisters
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
NCT05169593 · ClinicalTrials.gov ↗ · Crohn Disease
Phase 4 Recruiting Universitaire Ziekenhuizen KU Leuven Italy, Belgium
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
NCT06520397 · ClinicalTrials.gov ↗ · Crohn Disease
Phase 4 Recruiting Sixth Affiliated Hospital, Sun Yat-sen University China
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
NCT07303686 · ClinicalTrials.gov ↗ · Crohn Disease (CD), Ulcerative Colitis (UC)
Phase 4 Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre Canada
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967 · Plaque Psoriasis
Phase 3 Recruiting Bristol-Myers Squibb UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06453317 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Inflammatory Bowel Diseases
Phase 2 Recruiting Medical University of Lodz Poland
Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
NCT05725876 · ClinicalTrials.gov ↗ · Psoriasis, Crohn Disease
Phase 1 Recruiting University Medical Center Groningen Netherlands
Swiss Dermatology Network of Targeted Therapies (SDNTT)
NCT01706692 · ClinicalTrials.gov ↗ · Psoriasis
Observational Recruiting Swiss Dermatology Network for Targeted Therapies Switzerland
Korean College of Rheumatology Biologics and Targeted Therapy Registry
NCT01965132 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
Observational Recruiting Seoul National University Hospital South Korea
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT04372108 · Crohn Disease, Colitis, Ulcerative
Observational Recruiting Janssen Scientific Affairs, LLC USA
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031 · ClinicalTrials.gov ↗ · Crohn Disease, Stricture; Bowel, Intestinal Stricture
Observational Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
NCT06997055 · ClinicalTrials.gov ↗ · Crohn Disease, Plaque Psoriasis
Observational Recruiting Celltrion HealthCare France France
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT07444060 · CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease
Observational Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
NCT07694674 · ClinicalTrials.gov ↗ · Inflamatory Bowel Disease, Crohn Disease (CD)
Observational Recruiting Shanghai 10th People's Hospital China
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754 · Crohn's Disease
Phase 4 Active, closed Takeda USA, Canada
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611 · Crohn's Disease (CD)
Phase 3 Active, closed AbbVie UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Australia, Israel
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269 · Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Japan, Israel
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549 · Moderate to Severe Plaque Psoriasis
Phase 3 Active, closed UCB Biopharma SRL USA, Germany, Spain, Italy, Belgium, Poland, Czechia, Canada, Japan
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226 · Plaque Psoriasis
Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, Germany, Spain, Belgium, Denmark, Poland, Austria, Portugal, Canada, Australia
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411 · Crohn's Disease
Phase 2/3 Active, closed Janssen Research & Development, LLC UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
NCT03941132 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus
Phase 2/3 Active, closed University of British Columbia Canada
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488 · Psoriasis
Observational Active, closed Janssen-Cilag International NV UK, Germany, France, Netherlands, Belgium, Denmark, Switzerland, Austria, Norway
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555 · ClinicalTrials.gov ↗ · Crohn's Disease
Observational Active, closed Alimentiv Inc Canada
A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis
NCT06786507 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)
Observational Active, closed Helwan University Egypt

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Ustekinumab in the EU trials register (CTIS)

3 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ustekinumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
2026-526036-38-00 · Neoplasms
Phase 2 Authorised Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Netherlands
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
2024-514964-24-00 · CTIS ↗ · Digestive System Diseases
Phase 3 Authorised University Hospital Of Clermont-Ferrand France
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00 · CTIS ↗ · Therapeutics
Phase 2 Authorised Assistance Publique Hopitaux De Paris France
03

Ustekinumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

49 single-substance products containing Ustekinumab on the HPRA medicines list.

All 49 Irish products →

Supply shortages

No entry for Ustekinumab in the EMA, FDA or German BfArM shortage lists we track.

Recent approvals

  • UsgenaEMA · 17 Nov 2025 · biosimilar · Stada Arzneimittel AG
04

Conditions studied with Ustekinumab

21 conditions
Crohn Disease7Plaque Psoriasis3Psoriasis3Crohn's Disease3Colitis, Ulcerative2Stricture; Bowel2Crohn Disease (CD)2Ulcerative Colitis (UC)2Crohn's Disease (CD)1Arthritis, Psoriatic1Moderate to Severe Plaque Psoriasis1Intestinal Stricture1
All 21 conditions
Condition (as registered)Trials
Crohn Disease7
Plaque Psoriasis3
Psoriasis3
Crohn's Disease3
Colitis, Ulcerative2
Stricture; Bowel2
Crohn Disease (CD)2
Ulcerative Colitis (UC)2
Crohn's Disease (CD)1
Arthritis, Psoriatic1
Moderate to Severe Plaque Psoriasis1
Intestinal Stricture1
Inflamatory Bowel Disease1
CD - Crohn's Disease1
IBD - Inflammatory Bowel Disease1
Ulcerative Colitis1
Inflammatory Bowel Diseases1
Type 1 Diabetes Mellitus1
Rheumatoid Arthritis1
Ankylosing Spondylitis1
Psoriatic Arthritis1
05

Sponsors

lead sponsor per trial
Lead sponsorTrials
Janssen Research & Development, LLC3
Second Affiliated Hospital, Zhejiang University, School of Medicine2
Bristol-Myers Squibb1
Janssen-Cilag International NV1
AbbVie1
UCB Biopharma SRL1
Janssen Scientific Affairs, LLC1
Takeda1
Shanghai 10th People's Hospital1
Sixth Affiliated Hospital, Sun Yat-sen University1
Celltrion HealthCare France1
Universitaire Ziekenhuizen KU Leuven1
University Medical Center Groningen1
Medical University of Lodz1
Swiss Dermatology Network for Targeted Therapies1

+ 5 more sponsors in the trial list above.

06

By country register

RegisterTrialsRecruiting
Clinical trials in Canada92
Clinical trials in USA82
Clinical trials in Belgium82
Clinical trials in China75
Clinical trials in Germany71
Clinical trials in Poland72
Clinical trials in UK61
Clinical trials in France62
Clinical trials in Spain61
Clinical trials in Italy62
Clinical trials in Czechia41
Clinical trials in Japan41
Clinical trials in South Korea42
Clinical trials in Australia41
Clinical trials in Netherlands41
Clinical trials in Austria40
Clinical trials in Denmark31
Clinical trials in Brazil31
Clinical trials in Switzerland31
Clinical trials in Turkey30
Clinical trials in Israel30
Clinical trials in Sweden21
Clinical trials in Mexico21
Clinical trials in Taiwan21
Clinical trials in Portugal20
Clinical trials in Norway10
Clinical trials in India10
Clinical trials in Egypt10
EU register (CTIS)3—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

07

Related compounds

08

Questions about Ustekinumab trials

How many clinical trials are testing Ustekinumab?

23 current trials in our Canada, USA, Belgium, China, Germany, Poland, UK, France, Spain, Italy, Czechia, Japan, South Korea, Australia, Netherlands, Austria, Denmark, Brazil, Switzerland, Turkey, Israel, Sweden, Mexico, Taiwan, Portugal, Norway, India and Egypt registers name Ustekinumab (also registered as CNTO 1275) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Ustekinumab trials recruiting patients?

Yes. 13 of the 23 trials are recruiting: 2 with sites in Canada, 2 with sites in USA, 2 with sites in Belgium, 5 with sites in China, 1 with sites in Germany, 2 with sites in Poland, 1 with sites in UK, 2 with sites in France, 1 with sites in Spain, 2 with sites in Italy, 1 with sites in Czechia, 1 with sites in Japan, 2 with sites in South Korea, 1 with sites in Australia, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Brazil, 1 with sites in Switzerland, 1 with sites in Sweden, 1 with sites in Mexico and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Ustekinumab clinical trials?

Janssen Research & Development, LLC (3), Second Affiliated Hospital, Zhejiang University, School of Medicine (2), Bristol-Myers Squibb (1) and Janssen-Cilag International NV (1), among 20 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Ustekinumab licensed in Ireland?

Yes. The HPRA medicines list includes 49 single-substance products containing Ustekinumab, for example Fymskina 130 mg Concentrate for solution for infusion (Formycon AG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Ustekinumab shortage?

Not in the lists we track: Ustekinumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ustekinumab works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ustekinumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ustekinumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.